FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2593076788> ?p ?o ?g. }

• W2593076788 abstract "ABSTRACT Respiratory syncytial virus (RSV) causes severe respiratory disease in young children. Antibodies specific for the RSV prefusion F protein have guided RSV vaccine research, and in human serum, these antibodies contribute to >90% of the neutralization response; however, detailed insight into the composition of the human B cell repertoire against RSV is still largely unknown. In order to study the B cell repertoire of three healthy donors for specificity against RSV, CD27 + memory B cells were isolated and immortalized using BCL6 and Bcl-xL. Of the circulating memory B cells, 0.35% recognized RSV-A2-infected cells, of which 59% were IgA-expressing cells and 41% were IgG-expressing cells. When we generated monoclonal B cells selected for high binding to RSV-infected cells, 44.5% of IgG-expressing B cells and 56% of IgA-expressing B cells reacted to the F protein, while, unexpectedly, 41.5% of IgG-expressing B cells and 44% of IgA expressing B cells reacted to the G protein. Analysis of the G-specific antibodies revealed that 4 different domains on the G protein were recognized. These epitopes predicted cross-reactivity between RSV strain A (RSV-A) and RSV-B and matched the potency of antibodies to neutralize RSV in HEp-2 cells and in primary epithelial cell cultures. G-specific antibodies were also able to induce antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis of RSV-A2-infected cells. However, these processes did not seem to depend on a specific epitope. In conclusion, healthy adults harbor a diverse repertoire of RSV glycoprotein-specific antibodies with a broad range of effector functions that likely play an important role in antiviral immunity. IMPORTANCE Human RSV remains the most common cause of severe lower respiratory tract disease in premature babies, young infants, the elderly, and immunocompromised patients and plays an important role in asthma exacerbations. In developing countries, RSV lower respiratory tract disease has a high mortality. Without an effective vaccine, only passive immunization with palivizumab is approved for prophylactic treatment. However, highly potent RSV-specific monoclonal antibodies could potentially serve as a therapeutic treatment and contribute to disease control and mortality reduction. In addition, these antibodies could guide further vaccine development. In this study, we isolated and characterized several novel antibodies directed at the RSV G protein. This information can add to our understanding and treatment of RSV disease." @default.
• W2593076788 created "2017-03-16" @default.
• W2593076788 creator A5027506027 @default.
• W2593076788 creator A5037550875 @default.
• W2593076788 creator A5039767648 @default.
• W2593076788 creator A5054645034 @default.
• W2593076788 creator A5082873219 @default.
• W2593076788 creator A5084527419 @default.
• W2593076788 creator A5088693665 @default.
• W2593076788 creator A5088726045 @default.
• W2593076788 date "2017-05-15" @default.
• W2593076788 modified "2023-10-16" @default.
• W2593076788 title "Broadly Reactive Anti-Respiratory Syncytial Virus G Antibodies from Exposed Individuals Effectively Inhibit Infection of Primary Airway Epithelial Cells" @default.
• W2593076788 cites W115423185 @default.
• W2593076788 cites W1527926071 @default.
• W2593076788 cites W1550534458 @default.
• W2593076788 cites W1587614700 @default.
• W2593076788 cites W1921480186 @default.
• W2593076788 cites W1961361211 @default.
• W2593076788 cites W1981046587 @default.
• W2593076788 cites W1985960971 @default.
• W2593076788 cites W1991656907 @default.
• W2593076788 cites W2000714505 @default.
• W2593076788 cites W2004663239 @default.
• W2593076788 cites W2005761948 @default.
• W2593076788 cites W2008669330 @default.
• W2593076788 cites W2012873002 @default.
• W2593076788 cites W2030577907 @default.
• W2593076788 cites W2043056303 @default.
• W2593076788 cites W2082026765 @default.
• W2593076788 cites W2084126349 @default.
• W2593076788 cites W2100312529 @default.
• W2593076788 cites W2102146833 @default.
• W2593076788 cites W2114446982 @default.
• W2593076788 cites W2120949068 @default.
• W2593076788 cites W2122575257 @default.
• W2593076788 cites W2135560433 @default.
• W2593076788 cites W2136648677 @default.
• W2593076788 cites W2137682982 @default.
• W2593076788 cites W2137834917 @default.
• W2593076788 cites W2140516603 @default.
• W2593076788 cites W2140590997 @default.
• W2593076788 cites W2143237309 @default.
• W2593076788 cites W2152581975 @default.
• W2593076788 cites W2164807254 @default.
• W2593076788 cites W2198743132 @default.
• W2593076788 cites W2270869679 @default.
• W2593076788 cites W2274022023 @default.
• W2593076788 cites W2338072361 @default.
• W2593076788 cites W2563378637 @default.
• W2593076788 cites W2589772520 @default.
• W2593076788 cites W4239909494 @default.
• W2593076788 doi "https://doi.org/10.1128/jvi.02357-16" @default.
• W2593076788 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5411575" @default.
• W2593076788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28275185" @default.
• W2593076788 hasPublicationYear "2017" @default.
• W2593076788 type Work @default.
• W2593076788 sameAs 2593076788 @default.
• W2593076788 citedByCount "49" @default.
• W2593076788 countsByYear W25930767882018 @default.
• W2593076788 countsByYear W25930767882019 @default.
• W2593076788 countsByYear W25930767882020 @default.
• W2593076788 countsByYear W25930767882021 @default.
• W2593076788 countsByYear W25930767882022 @default.
• W2593076788 countsByYear W25930767882023 @default.
• W2593076788 crossrefType "journal-article" @default.
• W2593076788 hasAuthorship W2593076788A5027506027 @default.
• W2593076788 hasAuthorship W2593076788A5037550875 @default.
• W2593076788 hasAuthorship W2593076788A5039767648 @default.
• W2593076788 hasAuthorship W2593076788A5054645034 @default.
• W2593076788 hasAuthorship W2593076788A5082873219 @default.
• W2593076788 hasAuthorship W2593076788A5084527419 @default.
• W2593076788 hasAuthorship W2593076788A5088693665 @default.
• W2593076788 hasAuthorship W2593076788A5088726045 @default.
• W2593076788 hasBestOaLocation W25930767881 @default.
• W2593076788 hasConcept C153911025 @default.
• W2593076788 hasConcept C159047783 @default.
• W2593076788 hasConcept C159654299 @default.
• W2593076788 hasConcept C195616568 @default.
• W2593076788 hasConcept C203014093 @default.
• W2593076788 hasConcept C2522874641 @default.
• W2593076788 hasConcept C2778453870 @default.
• W2593076788 hasConcept C542903549 @default.
• W2593076788 hasConcept C54355233 @default.
• W2593076788 hasConcept C81885089 @default.
• W2593076788 hasConcept C86803240 @default.
• W2593076788 hasConceptScore W2593076788C153911025 @default.
• W2593076788 hasConceptScore W2593076788C159047783 @default.
• W2593076788 hasConceptScore W2593076788C159654299 @default.
• W2593076788 hasConceptScore W2593076788C195616568 @default.
• W2593076788 hasConceptScore W2593076788C203014093 @default.
• W2593076788 hasConceptScore W2593076788C2522874641 @default.
• W2593076788 hasConceptScore W2593076788C2778453870 @default.
• W2593076788 hasConceptScore W2593076788C542903549 @default.
• W2593076788 hasConceptScore W2593076788C54355233 @default.
• W2593076788 hasConceptScore W2593076788C81885089 @default.
• W2593076788 hasConceptScore W2593076788C86803240 @default.
• W2593076788 hasIssue "10" @default.
• W2593076788 hasLocation W25930767881 @default.
• W2593076788 hasLocation W25930767882 @default.

• next